Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Cho

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Clinical Practice (London, England)|February 5, 2013
Therapeutic challenges in advanced renal cell carcinomaDaniel C Cho
Oncotargets and Therapy|June 22, 2013
Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitorsDaniel C Cho
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2014
Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlookDaniel C Cho
Expert Opinion on Investigational Drugs|December 21, 2012
Perifosine in renal cell carcinomaNeeharika Srivastava, Daniel C Cho
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Novel Therapeutics Affecting Metabolic PathwaysSalman Punekar, Daniel C Cho
Therapy (London, England : 2004)|September 7, 2011
mTOR inhibitors in renal cell carcinomaChiara Battelli, Daniel C Cho
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2012
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?Daniel C Cho, Michael B Atkins
Journal of Kidney Cancer and VHL|December 28, 2020
Emerging Therapies for Advanced Clear Cell Renal Cell CarcinomaAlexander T Toth, Daniel C Cho
Current Cancer Drug Targets|December 25, 2012
Dual inhibition of PI3-kinase and mTOR in renal cell carcinomaDaniel C Cho, James W Mier
Hematology/Oncology Clinics of North America|July 19, 2011
Future directions in renal cell carcinoma: 2011 and beyondDaniel C Cho, Michael B Atkins
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Clinical Practice (London, England)|February 5, 2013
Therapeutic challenges in advanced renal cell carcinomaDaniel C Cho
Oncotargets and Therapy|June 22, 2013
Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitorsDaniel C Cho
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2014
Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlookDaniel C Cho
Expert Opinion on Investigational Drugs|December 21, 2012
Perifosine in renal cell carcinomaNeeharika Srivastava, Daniel C Cho
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Novel Therapeutics Affecting Metabolic PathwaysSalman Punekar, Daniel C Cho
Therapy (London, England : 2004)|September 7, 2011
mTOR inhibitors in renal cell carcinomaChiara Battelli, Daniel C Cho
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2012
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?Daniel C Cho, Michael B Atkins
Journal of Kidney Cancer and VHL|December 28, 2020
Emerging Therapies for Advanced Clear Cell Renal Cell CarcinomaAlexander T Toth, Daniel C Cho
Current Cancer Drug Targets|December 25, 2012
Dual inhibition of PI3-kinase and mTOR in renal cell carcinomaDaniel C Cho, James W Mier
Hematology/Oncology Clinics of North America|July 19, 2011
Future directions in renal cell carcinoma: 2011 and beyondDaniel C Cho, Michael B Atkins
Pageof 5